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There has beenmuch speculation in journals, as well as
social and traditional media about a link between
popularly used classes of drugs that inhibit the renin-
angiotensin system (RAS) and novel coronavirus
(severe acute respiratory syndrome coronavirus 2
[SARS-CoV-2]) infection or coronavirus disease 2019
(COVID-19) disease severity (1,2). After examining the
available evidence,we advise that inhibitors of theRAS
pathway should be continued in patients with COVID-
19 who are taking these drugs for evidence-based
indications. The putative link between SARS-CoV-
2 angiotensin-converting enzyme inhibitors (ACEis)
and angiotensin receptor blockers (ARBs) can be
rationalized by the biology of virus entry (3). The spike
protein of SARS-CoV-2 uses angiotensin-converting
enzyme 2 (ACE2) as a receptor to enter type II pneumo-
cytes or enterocytes (and likely, other cells). Although
ACE2 expression is low in lungs where prolyloligo-
peptidase is the main enzyme that metabolizes angio-
tensin II to angiotensin (1–7), the presence of ACE2
protein in type II pneumocytes seems important for
virus entry (4) (Figure 1). Many concerned physicians
and patients are conflicted about how to address
ACEis/ARBs vis-à-vis COVID-19. As concerned phy-
sicians and scientists working in this area, we summa-
rize theevidenceandcall forgreaterunderstandingand
systematic data gathering rather than hasty decision
making on the basis of incomplete or inaccurate in-
formation or unjustified extrapolations. The current
scientific and clinical questions are as follows. Is there a
link between hypertension and increased risk of viral
infection in humans? Are patients on ACEis/ARBs at
increased risk of infection or severity of disease? Does
modulation of these drugs (starting, stopping, or
continuing) lead to better or worse outcomes in
COVID-19?
A hypothesized relationship between hypertension
and COVID-19mortality is not supported at this time
by robust data. It is known that increasing age
strongly correlates with hypertension and has been
associated with higher mortality from COVID-19.
However, none of the reports have adjusted for age or
provided age-stratified data for the hypertension and
mortality association to understand if this is a ro-
bust finding (5).
Some animal studies have demonstrated increased
cardiac ACE2mRNA levels (among other organs, such
as kidney vasculature) and activity after ACEi or ARB
therapy (6,7). However, others have not shown en-
hanced ACE2 levels after ACEi or ARB treatment (8).
Moreover, data inhumanshavenot consistently shown
increased ACE2 levels, and good-quality data are
lacking because full-length ACE2 anchored to cells is
not easily measurable (9). Moreover, the clinical sig-
nificance of this biology in COVID-19 infection is
uncertain. Thus, these data do not provide sufficient
evidence linking RAS inhibitors to upregulation of
ACE2 in humans and subsequent SARS-CoV-
2 infection.
The complex relationship between viral protein
binding to ACE2, RAS components, and viral patho-
genicity is not fully understood (Figure 1). Evidence
also supports the possibility that ACEis and/or ARBs
could reduce the severity of COVID-19 infection. It is
also not clear if ARBs could exert preferential effects
over ACEis. These questions require more rigorous
studies. Severe acute respiratory distress syndrome
infection is associatedwithdecreasedACE2 expression
in rodent models, and treatment with losartan reduces
lung injury (10). Taken together, these gaps in knowl-
edge highlight the urgent need to perform careful
clinical and basic research on this topic.
ACEi/ARBs are the most widely used classes of
antihypertensiveagents,withclinicallyprovenbenefits
in patients with hypertension, diabetes, heart failure,
andCKD. StoppingACEis andARBs in asymptomatic,
stable patients with heart failure, kidney disease, or
hypertensionwill disrupt clinical care, necessitate extra
visits, and increase health care utilization, thus dis-
rupting attempts at social distancing. Preclinical stud-
ies (some animalmodels) actually support the idea that
ACEi and/orARBuse could be protective in the setting
of viral pneumonias, including coronavirus infection,
but no such data are available in humans (10,11).
Retrospective and observational data are still being
analyzed and reported from the earliest affected re-
gions, and new data are likely to emerge over the
coming weeks to months (clinicaltrials.gov:
NCT04311177andNCT04312009). Thedata are coming
fast and rapidly changing, and therefore, we have
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created a website, which is being updated in real time to
provide a more reliable source of information (http://
www.nephjc.com/news/covidace2). We believe that it
is important to provide the medical community with
updates as they emerge on the use of RAS inhibitors in the
context of COVID-19.
We strongly suggest to the scientific community to
withhold judgement on this issue due to an incomplete
understanding of the risk or benefit of these medications.
We believe that there is equipoise in thismatter, and the only
way to establish an evidence base for these decisions is to
study these questions in clinical trials or thorough analysis
of observational data using appropriate methodology
when a trial is not ethical. Randomized clinical trials are in
the planning stages at the University of Minnesota. Only
throughsystematic andwellplannedandexecutedbasic and
clinical studies will we answer the scientific and clinical
questions above. After reviewing the available data, our
conclusion is that the link between hypertension and/or the
useofRAS inhibitors (ACEisorARBs) inpatientswithSARS-
CoV-2 infection and COVID-19 outcomes has not been
firmly established. There is no definitive evidence linking
RAS inhibition with increased ACE2 expression and sub-
sequent enhanced SARS-CoV-2 infection. Furthermore,
there is preclinical data suggesting a potential benefit with
RAS inhibition in SARS-CoV-1. Our recommendation is for
patients to continue the use of prescribed RAS inhibitors
unless there exists an evidence-based indication to discon-
tinue these important life-saving medications.
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